The company hopes to complete proof of principle for a companion diagnostic to identify patients with PCa who are likely to need aggressive treatment.

NEW YORK — Sysmex America said on Wednesday that it has received licensing from Health Canada for its CN-3000 and CN-6000 automated blood coagulation analyzers. The CN-3000 and CN-6000 are designed ...

The company plans to bring to market in the coming years a series of microarray-based tests for autoimmune diseases and allergies, among other tests.